Answers are grounded in this paper and cite their sources.
Economic evaluation highlights ADHD medication shortages in the US, suggesting policies to improve supply chain resilience.
These patterns align with manufacturers' reports to the US Food and Drug Administration citing a shortage of the active ingredient as the cause of backorders. More broadly, this economic evaluation reframes the discussion of ADHD medication shortages beyond DEA quotas, highlighting the vulnerability of US pharmaceutical manufacturing to international supply chain disruptions and underscoring the need for policies that strengthen supply chain resilience.
No takes yet. Share an insight, caveat, or question.
Currie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: